HC ANDERSEN CAPITAL

Ascelia Pharma – Update on re-evaluation of Sparkle headline data

Name: Ascelia Pharma - Update on re-evaluation of Sparkle headline data
Start: 2023-09-20T10:00:00+0200
End: 2023-09-20T10:30:00+0200

AUTHOR

Mie

DATE

14. September 2023

Ascelia Pharma – Update on re-evaluation of Sparkle headline data

Ascelia Pharma - Update on re-evaluation of Sparkle headline data 20 SeptemberSep 2023 10:00 - 10:30Online Event

Information

Ascelia Pharma - Update on re-evaluation of Sparkle headline data 20 SeptemberSep 2023 10:00 - 10:30

Ascelia Pharma - Update on re-evaluation of Sparkle headline data Online Event

Pharma Equity Group – Introduction to new CMO (Chief Medical Officer) Dr. Christopher M. Burton and dive into pipeline

Aktier med Friis – uge 38

Explore our services

INFORMATION

Bredgade 23B 2. sal
1260 København K
View on map
Phone: 28 74 66 40
CVR: 41474793

About

What we do

HC Andersen Capital was established in 2020 and is at the forefront of digital Investor Relations, amplifying market presence.

Our tailored services encompass IR and ESG advisory, Legal Support, cutting-edge digital solutions such as IR websites and IR distribution software, Commissioned Research, Corporate Finance advisory and more. We are proudly Certified Adviser on Nasdaq First North Copenhagen.

About us

What we do in short

Advisory

IR Services

Our Community

Ascelia Pharma – Update on re-evaluation of Sparkle headline data

Ascelia Pharma – Update on re-evaluation of Sparkle headline data

Information

Explore our services

INFORMATION

About

What we do

2024 - HC Andersen Capital